可切除食管胃腺癌围手术期化疗联合或不联合贝伐珠单抗(英国医学研究理事会ST03):多中心、开放标签、随机2-3期试验的主要分析结果
这项多中心开放标签随机2-3期试验纳入1063例可切除食管胃腺癌患者,比较围手术期表柔比星+顺铂+卡培他滨化疗联合或不联合贝伐珠单抗的疗效与安全性。结果显示联合贝伐珠单抗未改善总生存,3年总生存率化疗组50.3% vs 联合组48.1%(HR 1.08,95%CI 0.91-1.29;P=0.36),且贝伐珠单抗组伤口愈合并发症和吻合口漏发生率更高。
要点
- 联合贝伐珠单抗未改善可切除食管胃腺癌患者的总生存(HR 1.08,95%CI 0.91-1.29;P=0.36)。
- 贝伐珠单抗组伤口愈合并发症发生53例(12%),化疗组33例(7%)。
- 食管胃切除术后吻合口漏联合组52/220(24%),化疗组23/233(10%)。
核心结论
- 本试验结果不支持在可切除胃、食管胃结合部或下段食管腺癌患者中,将贝伐珠单抗联合围手术期表柔比星、顺铂和卡培他滨化疗使用。
- 贝伐珠单抗还可能与伤口愈合受损相关。
研究设计与样本
- 多中心、随机、开放标签2-3期试验,从英国87家医院和癌症中心招募18岁及以上组织学证实可切除食管胃腺癌患者。
- 患者1:1随机分配接受围手术期表柔比星+顺铂+卡培他滨化疗或化疗联合贝伐珠单抗,均联合手术。
- 对照组术前和术后各3周期化疗:第1天表柔比星50 mg/m2和顺铂60 mg/m2,第1-21天口服卡培他滨1250 mg/m2。
- 试验组接受与对照组相同治疗,另在每个化疗周期第1天静脉给予贝伐珠单抗7.5 mg/kg,化疗结束后每21天再给6次作为维持治疗。
- 随机化通过电话至医学研究理事会临床试验单位,采用最小化算法并包含随机元素,按化疗中心、肿瘤部位和肿瘤分期分层。
主要发现
- 2007年10月31日至2014年3月25日共入组1063例患者,随机接受单纯化疗(n=533)或化疗联合贝伐珠单抗(n=530)。
- 分析时记录508例死亡(单纯化疗组248例,化疗联合贝伐珠单抗组260例)。
- 3年总生存率单纯化疗组50.3%(95%CI 45.5-54.9),化疗联合贝伐珠单抗组48.1%(43.2-52.7)(HR 1.08,95%CI 0.91-1.29;P=0.36)。
- 除中性粒细胞减少外,两组均无其他3级或更严重毒性反应发生率超过10%。
- 伤口愈合并发症贝伐珠单抗组53例(12%),单纯化疗组33例(7%)。
临床怎么用
- 原文结论认为本试验结果不提供任何证据支持在可切除胃、食管胃结合部或下段食管腺癌患者中使用贝伐珠单抗联合围手术期表柔比星、顺铂和卡培他滨化疗。
- 原文指出贝伐珠单抗还可能与伤口愈合受损相关。
局限性
- 原文报告在试验接近结束时,因化疗联合贝伐珠单抗组食管胃切除术后吻合口漏率更高(52/220[24%] vs 23/233[10%]),停止了计划行食管胃切除术的下段食管或结合部肿瘤患者的招募。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagogastric adenocarcinoma. Bevacizumab, a monoclonal antibody against VEGF, improves the proportion of patients responding to treatment in advanced gastric cancer. We aimed to assess the safety and efficacy of adding bevacizumab to peri-operative chemotherapy in patients with resectable gastric, oesophagogastric junction, or lower oesophageal adenocarcinoma. METHODS: In this multicentre, randomised, open-label phase 2-3 trial, we recruited patients aged 18 years and older with histologically proven, resectable oesophagogastric adenocarcinoma from 87 UK hospitals and cancer centres. We randomly assigned patients 1:1 to receive peri-operative epirubicin, cisplatin, and capecitabine chemotherapy or chemotherapy plus bevacizumab, in addition to surgery. Patients in the control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1-21. Patients in the investigational group received the same treatment as the control group plus 7·5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy, as maintenance treatment. Randomisation was done by means of a telephone call to the Medical Research Council Clinical Trials Unit, where staff used a computer programme that implemented a minimisation algorithm with a random element to establish the allocation for the patient at the point of randomisation. Patients were stratified by chemotherapy centre, site of tumour, and tumour stage. The primary outcome for the phase 3 stage of the trial was overall survival (defined as the time from randomisation until death from any cause), analysed in the intention-to-treat population. Here, we report the primary analysis results of the trial; all patients have completed treatment and the required number of primary outcome events has been reached. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN 46020948, and with ClinicalTrials.gov, number NCT00450203. FINDINGS: Between Oct 31, 2007, and March 25, 2014, 1063 patients were enrolled and randomly assigned to receive chemotherapy alone (n=533) or chemotherapy plus bevacizumab (n=530). At the time of analysis, 508 deaths were recorded (248 in the chemotherapy alone group and 260 in the chemotherapy plus bevacizumab group). 3-year overall survival was 50·3% (95% CI 45·5-54·9) in the chemotherapy alone group and 48·1% (43·2-52·7) in the chemotherapy plus bevacizumab group (hazard ratio [HR] 1·08, 95% CI 0·91-1·29; p=0·36). Apart from neutropenia no other toxic effects were reported at grade 3 or worse severity in more than 10% of patients in either group. Wound healing complications were more prevalent in the bevacizumab group, occurring in 53 (12%) patients in this group compared with 33 (7%) patients in the chemotherapy alone group. In patients who underwent oesophagogastrectomy, post-operative anastomotic leak rates were higher in the chemotherapy plus bevacizumab group (23 [10%] of 233 in the chemotherapy alone group vs 52 [24%] of 220 in the chemotherapy plus bevacizumab group); therefore, recruitment of patients with lower oesophageal or junctional tumours planned for an oesophagogastric resection was stopped towards the end of the trial. Serious adverse events for all patients included anastomotic leaks (30 events in chemotherapy alone group vs 69 in the chemotherapy plus bevacizumab group), and infections with normal neutrophil count (42 events vs 53). INTERPRETATION: The results of this trial do not provide any evidence for the use of bevacizumab in combination with peri-operative epiribicin, cisplatin, and capecitabine chemotherapy for patients with resectable gastric, oesophagogastric junction, or lower oesophageal adenocarcinoma. Bevacizumab might also be associated with impaired wound healing. FUNDING: Cancer Research UK, MRC Clinical Trials Unit at University College London, and F Hoffmann-La Roche Limited.
引用
- Cunningham D, Stenning SP, Smyth EC, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol. 2017. PMID: 28163000. doi:10.1016/S1470-2045(17)30043-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。